Liu Yao-Lung, Liu Jiung-Hsiun, Wang I-Kuan, Ju Shu-Woei, Yu Tung-Min, Chen I-Ru, Liu Yu-Ching, Huang Chung-Ming, Lin Shih-Yi, Chang Chiz-Tzung, Huang Chiu-Ching
Graduate Institute of Clinical Medical Science, China Medical University College of Medicine, Taichung 404, Taiwan - Department of Internal Medicine, China Medical University College of Medicine, Taichung 404, Taiwan - Division of Nephrology, China Medical University Hospital, Taichung 404, Taiwan.
Department of Internal Medicine, China Medical University College of Medicine, Taichung 404, Taiwan - Division of Nephrology, China Medical University Hospital, Taichung 404, Taiwan.
Biomedicine (Taipei). 2017 Mar;7(1):1. doi: 10.1051/bmdcn/2017070101. Epub 2017 Mar 3.
Previous study on association between pro-inflammatory cytokines and mortality in PD population is limited. We aimed to investigate here.
Total 50 patients who underwent incident PD were enrolled in this study. We measured the titers of pro-inflammatory cytokines Interleukin-18(IL-18), Interleukin-6 (IL-6), and Interleukin-1ß (IL-1ß). Study outcomes were all-cause mortality, cardiovascular-related mortality, and infection-caused mortality. Cox-regression model was used.
In this 7 year prospective study, IL-18 ≥ 804.3pg/ml, IL-6 ≥ 3.92 pg/ml, IL-1ß ≥ 0.86pg/ml, age ≥ 50 years-old, and existence of diabetes could be used as individual significant predictors for mortality in PD patients. Higher titers of IL-6 were associated with lower averaging albumin levels within 1 year of PD. Increasing numbers of these risk markers of mortality was associated with decreasing survival advantages (P = 0.001).
Age ≥ 50 years-old, diabetes, and inflammatory cytokines profiles at the start of PD therapy could predict for 7-year mortality in PD population.
先前关于帕金森病(PD)患者群体中促炎细胞因子与死亡率之间关联的研究有限。我们旨在对此进行调查。
本研究纳入了50例初发帕金森病患者。我们检测了促炎细胞因子白细胞介素-18(IL-18)、白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β)的水平。研究结局为全因死亡率、心血管相关死亡率和感染所致死亡率。采用Cox回归模型。
在这项为期7年的前瞻性研究中,IL-18≥804.3pg/ml、IL-6≥3.92pg/ml、IL-1β≥0.86pg/ml、年龄≥50岁以及存在糖尿病可作为帕金森病患者死亡率的个体显著预测因素。较高水平的IL-6与帕金森病发病1年内较低的平均白蛋白水平相关。这些死亡率风险标志物数量的增加与生存优势的降低相关(P = 0.001)。
年龄≥50岁、糖尿病以及帕金森病治疗开始时的炎症细胞因子谱可预测帕金森病患者群体的7年死亡率。